Cargando…
A metabolic profile of polyamines in parkinson disease: A promising biomarker
OBJECTIVE: Aging is the highest risk factor for Parkinson disease (PD). Under physiological conditions, spermidine and spermine experimentally enhance longevity via autophagy induction. Accordingly, we evaluated the ability of each polyamine metabolite to act as an age‐related, diagnostic, and sever...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772170/ https://www.ncbi.nlm.nih.gov/pubmed/31155745 http://dx.doi.org/10.1002/ana.25516 |
_version_ | 1783455852921880576 |
---|---|
author | Saiki, Shinji Sasazawa, Yukiko Fujimaki, Motoki Kamagata, Koji Kaga, Naoko Taka, Hikari Li, Yuanzhe Souma, Sanae Hatano, Taku Imamichi, Yoko Furuya, Norihiko Mori, Akio Oji, Yutaka Ueno, Shin‐Ichi Nojiri, Shuko Miura, Yoshiki Ueno, Takashi Funayama, Manabu Aoki, Shigeki Hattori, Nobutaka |
author_facet | Saiki, Shinji Sasazawa, Yukiko Fujimaki, Motoki Kamagata, Koji Kaga, Naoko Taka, Hikari Li, Yuanzhe Souma, Sanae Hatano, Taku Imamichi, Yoko Furuya, Norihiko Mori, Akio Oji, Yutaka Ueno, Shin‐Ichi Nojiri, Shuko Miura, Yoshiki Ueno, Takashi Funayama, Manabu Aoki, Shigeki Hattori, Nobutaka |
author_sort | Saiki, Shinji |
collection | PubMed |
description | OBJECTIVE: Aging is the highest risk factor for Parkinson disease (PD). Under physiological conditions, spermidine and spermine experimentally enhance longevity via autophagy induction. Accordingly, we evaluated the ability of each polyamine metabolite to act as an age‐related, diagnostic, and severity‐associated PD biomarker. METHODS: Comprehensive metabolome analysis of plasma was performed in Cohort A (controls, n = 45; PD, n = 145), followed by analysis of 7 polyamine metabolites in Cohort B (controls, n = 49; PD, n = 186; progressive supranuclear palsy, n = 19; Alzheimer disease, n = 23). Furthermore, 20 patients with PD who were successively examined within Cohort B were studied using diffusion tensor imaging (DTI). Association of each polyamine metabolite with disease severity was assessed according to Hoehn and Yahr stage (H&Y) and Unified Parkinson's Disease Rating Scale motor section (UPDRS‐III). Additionally, the autophagy induction ability of each polyamine metabolite was examined in vitro in various cell lines. RESULTS: In Cohort A, N8‐acetylspermidine and N‐acetylputrescine levels were significantly and mildly elevated in PD, respectively. In Cohort B, spermine levels and spermine/spermidine ratio were significantly reduced in PD, concomitant with hyperacetylation. Furthermore, N1,N8‐diacetylspermidine levels had the highest diagnostic value, and correlated with H&Y, UPDRS‐III, and axonal degeneration quantified by DTI. The spermine/spermidine ratio in controls declined with age, but was consistently suppressed in PD. Among polyamine metabolites, spermine was the strongest autophagy inducer, especially in SH‐SY5Y cells. No significant genetic variations in 5 genes encoding enzymes associated with spermine/spermidine metabolism were detected compared with controls. INTERPRETATION: Spermine synthesis and N1,N8‐diacetylspermidine may respectively be useful diagnostic and severity‐associated biomarkers for PD. ANN NEUROL 2019;86:251–263 |
format | Online Article Text |
id | pubmed-6772170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67721702019-10-07 A metabolic profile of polyamines in parkinson disease: A promising biomarker Saiki, Shinji Sasazawa, Yukiko Fujimaki, Motoki Kamagata, Koji Kaga, Naoko Taka, Hikari Li, Yuanzhe Souma, Sanae Hatano, Taku Imamichi, Yoko Furuya, Norihiko Mori, Akio Oji, Yutaka Ueno, Shin‐Ichi Nojiri, Shuko Miura, Yoshiki Ueno, Takashi Funayama, Manabu Aoki, Shigeki Hattori, Nobutaka Ann Neurol Research Articles OBJECTIVE: Aging is the highest risk factor for Parkinson disease (PD). Under physiological conditions, spermidine and spermine experimentally enhance longevity via autophagy induction. Accordingly, we evaluated the ability of each polyamine metabolite to act as an age‐related, diagnostic, and severity‐associated PD biomarker. METHODS: Comprehensive metabolome analysis of plasma was performed in Cohort A (controls, n = 45; PD, n = 145), followed by analysis of 7 polyamine metabolites in Cohort B (controls, n = 49; PD, n = 186; progressive supranuclear palsy, n = 19; Alzheimer disease, n = 23). Furthermore, 20 patients with PD who were successively examined within Cohort B were studied using diffusion tensor imaging (DTI). Association of each polyamine metabolite with disease severity was assessed according to Hoehn and Yahr stage (H&Y) and Unified Parkinson's Disease Rating Scale motor section (UPDRS‐III). Additionally, the autophagy induction ability of each polyamine metabolite was examined in vitro in various cell lines. RESULTS: In Cohort A, N8‐acetylspermidine and N‐acetylputrescine levels were significantly and mildly elevated in PD, respectively. In Cohort B, spermine levels and spermine/spermidine ratio were significantly reduced in PD, concomitant with hyperacetylation. Furthermore, N1,N8‐diacetylspermidine levels had the highest diagnostic value, and correlated with H&Y, UPDRS‐III, and axonal degeneration quantified by DTI. The spermine/spermidine ratio in controls declined with age, but was consistently suppressed in PD. Among polyamine metabolites, spermine was the strongest autophagy inducer, especially in SH‐SY5Y cells. No significant genetic variations in 5 genes encoding enzymes associated with spermine/spermidine metabolism were detected compared with controls. INTERPRETATION: Spermine synthesis and N1,N8‐diacetylspermidine may respectively be useful diagnostic and severity‐associated biomarkers for PD. ANN NEUROL 2019;86:251–263 John Wiley & Sons, Inc. 2019-07-01 2019-08 /pmc/articles/PMC6772170/ /pubmed/31155745 http://dx.doi.org/10.1002/ana.25516 Text en © 2019 The Authors Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Saiki, Shinji Sasazawa, Yukiko Fujimaki, Motoki Kamagata, Koji Kaga, Naoko Taka, Hikari Li, Yuanzhe Souma, Sanae Hatano, Taku Imamichi, Yoko Furuya, Norihiko Mori, Akio Oji, Yutaka Ueno, Shin‐Ichi Nojiri, Shuko Miura, Yoshiki Ueno, Takashi Funayama, Manabu Aoki, Shigeki Hattori, Nobutaka A metabolic profile of polyamines in parkinson disease: A promising biomarker |
title | A metabolic profile of polyamines in parkinson disease: A promising biomarker |
title_full | A metabolic profile of polyamines in parkinson disease: A promising biomarker |
title_fullStr | A metabolic profile of polyamines in parkinson disease: A promising biomarker |
title_full_unstemmed | A metabolic profile of polyamines in parkinson disease: A promising biomarker |
title_short | A metabolic profile of polyamines in parkinson disease: A promising biomarker |
title_sort | metabolic profile of polyamines in parkinson disease: a promising biomarker |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6772170/ https://www.ncbi.nlm.nih.gov/pubmed/31155745 http://dx.doi.org/10.1002/ana.25516 |
work_keys_str_mv | AT saikishinji ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT sasazawayukiko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT fujimakimotoki ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT kamagatakoji ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT kaganaoko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT takahikari ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT liyuanzhe ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT soumasanae ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT hatanotaku ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT imamichiyoko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT furuyanorihiko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT moriakio ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT ojiyutaka ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT uenoshinichi ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT nojirishuko ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT miurayoshiki ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT uenotakashi ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT funayamamanabu ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT aokishigeki ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT hattorinobutaka ametabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT saikishinji metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT sasazawayukiko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT fujimakimotoki metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT kamagatakoji metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT kaganaoko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT takahikari metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT liyuanzhe metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT soumasanae metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT hatanotaku metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT imamichiyoko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT furuyanorihiko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT moriakio metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT ojiyutaka metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT uenoshinichi metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT nojirishuko metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT miurayoshiki metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT uenotakashi metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT funayamamanabu metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT aokishigeki metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker AT hattorinobutaka metabolicprofileofpolyaminesinparkinsondiseaseapromisingbiomarker |